Robert G. Bristow - Publications

Medical Biophysics University of Toronto, Toronto, ON, Canada 
Molecular Biology, Cell Biology, Biochemistry, Oncology, General Biophysics

217 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, Bristow RG, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Green D, Bayley A, Helou J, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology. PMID 33685838 DOI: 10.1016/j.eururo.2021.02.031  0.4
2021 Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer. Nature Reviews. Disease Primers. 7: 9. PMID 33542230 DOI: 10.1038/s41572-020-00243-0  1
2020 Brastianos HC, Murgic J, Salcedo A, Chua MLK, Meng A, Fraser M, Brundage M, Fleshner NE, van der Kwast T, Bristow RG, Boutros PC, Berlin A. Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. European Urology Oncology. PMID 32605887 DOI: 10.1016/j.euo.2020.06.005  1
2020 Glicksman RM, Metser U, Valliant J, Chung PW, Fleshner NE, Bristow RG, Green D, Finelli A, Hamilton R, Stanescu T, Hussey D, Catton C, Gospodarowicz M, Warde P, Bayley A, et al. [F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. Bmj Open. 10: e035959. PMID 32327479 DOI: 10.1136/Bmjopen-2019-035959  0.4
2020 Rebello RJ, Bristow RG. Intermediate Risk Prostate Cancer: Disease Heterogeneity Linked to Measurable Biological Features. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 32147317 DOI: 10.1016/j.clon.2019.11.002  1
2020 Bhandari V, Li CH, Bristow RG, Boutros PC. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nature Communications. 11: 737. PMID 32024819 DOI: 10.1038/s41467-019-14052-x  1
2020 Zhou S, Hawley JR, Soares F, Grillo G, Teng M, Madani Tonekaboni SA, Hua JT, Kron KJ, Mazrooei P, Ahmed M, Arlidge C, Yun HY, Livingstone J, Huang V, Yamaguchi TN, ... ... Bristow RG, et al. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature Communications. 11: 441. PMID 31974375 DOI: 10.1038/s41467-020-14318-9  1
2019 Mazrooei P, Kron KJ, Zhu Y, Zhou S, Grillo G, Mehdi T, Ahmed M, Severson TM, Guilhamon P, Armstrong NS, Huang V, Yamaguchi TN, Fraser M, van der Kwast T, Boutros PC, ... ... Bristow RG, et al. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. Cancer Cell. PMID 31735626 DOI: 10.1016/j.ccell.2019.10.005  1
2019 Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi TN, ... ... Bristow RG, et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature Medicine. PMID 31591588 DOI: 10.1038/S41591-019-0579-Z  1
2019 Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, ... Bristow RG, et al. Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome. Journal of the National Cancer Institute. PMID 31161221 DOI: 10.1093/jnci/djz112  1
2019 Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, ... ... Bristow RG, et al. The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell. 35: 414-427.e6. PMID 30889379 DOI: 10.1016/j.ccell.2019.02.005  1
2019 Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP. The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews. Urology. PMID 30808988 DOI: 10.1038/s41585-019-0164-8  0.52
2019 Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, ... ... Bristow RG, et al. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 176: 831-843.e22. PMID 30735634 DOI: 10.1016/j.cell.2019.01.025  1
2019 Jiang DM, Jiang H, Chung PWM, Zlotta AR, Fleshner NE, Bristow RG, Berlin A, Kulkarni GS, Alimohamed NS, Lo G, Sridhar SS. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 17: 38-45. PMID 30686350 DOI: 10.1016/j.clgc.2018.09.021  0.4
2019 Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, ... ... Bristow RG, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications. 10: 278. PMID 30655535 DOI: 10.1038/S41467-018-08133-6  1
2019 Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, ... ... Bristow RG, et al. Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics. PMID 30643250 DOI: 10.1038/s41588-018-0318-2  1
2019 Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A. A phase I pilot study of pre-operative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes. International Journal of Radiation Oncology, Biology, Physics. PMID 30625410 DOI: 10.1016/j.ijrobp.2018.12.054  0.4
2019 Rebello RJ, Oing C, Gillessen S, Bristow RG. and Prognosis in mCRPC Survival: Biology or Coincidence? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30610102 DOI: 10.1158/1078-0432.CCR-18-3401  1
2018 Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, ... ... Bristow RG, et al. Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell. 34: 996-1011.e8. PMID 30537516 DOI: 10.1016/J.Ccell.2018.10.016  1
2018 Cooper CI, Yao D, Sendorek DH, Yamaguchi TN, P'ng C, Houlahan KE, Caloian C, Fraser M, Ellrott K, Margolin AA, Bristow RG, Stuart JM, Boutros PC. Valection: design optimization for validation and verification studies. Bmc Bioinformatics. 19: 339. PMID 30253747 DOI: 10.1186/s12859-018-2391-z  1
2018 Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, et al. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. Bmc Urology. 18: 78. PMID 30200929 DOI: 10.1186/S12894-018-0392-X  0.4
2018 Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. International Journal of Radiation Oncology, Biology, Physics. PMID 30170099 DOI: 10.1016/J.Ijrobp.2018.08.030  1
2018 Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, ... ... Bristow RG, et al. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. Ebiomedicine. PMID 29729848 DOI: 10.1016/J.Ebiom.2018.04.019  1
2018 Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, Fox NS, Chua MLK, Yamaguchi TN, Heisler LE, Livingstone J, Wintersinger J, Yousif F, Lalonde E, Rouette A, ... ... Bristow RG, et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell. PMID 29681457 DOI: 10.1016/j.cell.2018.03.029  1
2018 Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, ... ... Bristow RG, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics. PMID 29662167 DOI: 10.1038/S41588-018-0086-Z  1
2018 Böttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, Yousif F, Fraser M, Bristow RG, van der Kwast T, Boutros PC, Jenster G, van Leenders GJLH. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. Bmc Cancer. 18: 8. PMID 29295717 DOI: 10.1186/s12885-017-3976-z  1
2017 Briollais L, Bristow RG, Boutros PC, Zlotta AR. Response. Journal of the National Cancer Institute. 109. PMID 30053077 DOI: 10.1093/jnci/djx122  1
2017 Fraser M, Boutros PC, Bristow RG. A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer. European Urology. PMID 29275835 DOI: 10.1016/j.eururo.2017.11.029  1
2017 Berlin A, Ahmad AE, Chua MLK, Moraes FY, Jiang H, Komisarenko M, Trimilshina N, Raziee H, Hosni A, Murgic J, Chung P, Bristow RG, Finelli A. Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-Front Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 29249526 DOI: 10.1016/j.ijrobp.2017.10.041  0.4
2017 Sendorek DH, Lalonde E, Yao CQ, Sabelnykova VY, Bristow RG, Boutros PC. NanoStringNormCNV: Pre-processing of NanoString CNV data. Bioinformatics (Oxford, England). PMID 29112706 DOI: 10.1093/bioinformatics/btx707  1
2017 Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua MLK, Fraser M, Favero F, Lawerenz C, Plass C, Sauter G, ... ... Bristow RG, et al. Mitochondrial mutations drive prostate cancer aggression. Nature Communications. 8: 656. PMID 28939825 DOI: 10.1038/S41467-017-00377-Y  1
2017 Kron KJ, Murison A, Zhou S, Huang V, Yamaguchi TN, Shiah YJ, Fraser M, van der Kwast T, Boutros PC, Bristow RG, Lupien M. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nature Genetics. PMID 28783165 DOI: 10.1038/ng.3930  1
2017 Shiah YJ, Fraser M, Bristow RG, Boutros PC. Comparison of Pre-processing Methods for Infinium HumanMethylation450 BeadChip Array. Bioinformatics (Oxford, England). PMID 28605401 DOI: 10.1093/bioinformatics/btx372  1
2017 Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, ... ... Bristow RG, et al. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology. PMID 28511883 DOI: 10.1016/j.eururo.2017.04.034  1
2017 Raziee H, Moraes FY, Murgic J, Chua MLK, Pintilie M, Chung P, Ménard C, Bayley A, Gospodarowicz M, Warde P, Craig T, Catton C, Bristow RG, Jaffray DA, Berlin A. Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28434799 DOI: 10.1016/j.radonc.2017.04.003  0.4
2017 Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Juvet T, Prassas I, Trachtenberg J, Toi A, Fraser M, ... ... Bristow RG, et al. Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute. 109. PMID 28376164 DOI: 10.1093/Jnci/Djw258  1
2017 Hosni A, Rosewall T, Craig T, Kong V, Bayley A, Berlin A, Bristow R, Catton C, Warde P, Chung P. The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiation Oncology (London, England). 12: 50. PMID 28279179 DOI: 10.1186/s13014-017-0787-y  0.4
2017 Murphy DG, Risbridger GP, Bristow RG, Sandhu S. The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. European Urology. PMID 28131466 DOI: 10.1016/j.eururo.2017.01.025  1
2017 Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, ... ... Bristow RG, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. PMID 28068672 DOI: 10.1038/nature20788  1
2017 Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, ... ... Bristow RG, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications. 8: 13671. PMID 28067867 DOI: 10.1038/ncomms13671  1
2016 Lieng H, Pintilie M, Bayley A, Berlin A, Bristow R, Chung P, Gospodarowicz M, Huang R, Ménard C, Warde P, Catton C. Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 27838147 DOI: 10.1016/j.radonc.2016.10.017  0.4
2016 Lalonde E, Alkallas R, Chua ML, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, ... ... Bristow RG, et al. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology. PMID 27815082 DOI: 10.1016/j.eururo.2016.10.013  1
2016 Ghiam AF, Taeb S, Huang X, Jahangiri S, Ray J, Hoey C, Fokas E, Vesprini D, Bristow RG, Boutros PC, Liu SK. The Biological Role and Clinical Significance of Long Noncoding RNA Urothelial Carcinoma Associated 1 (UCA1) in Prostate Cancer (PCa). International Journal of Radiation Oncology, Biology, Physics. 96: S56. PMID 27675961 DOI: 10.1016/j.ijrobp.2016.06.145  1
2016 Lieng H, Pintilie M, Berlin A, Bayley A, Bristow RG, Chung P, Gospodarowicz MK, Menard C, Warde PR, Catton CN. Long-Term Outcomes of a Phase 2 Trial of Moderate Hypofractionated Image Guided Intensity Modulated Radiation Therapy (IG-IMRT) for Localized Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: S32-S33. PMID 27675903 DOI: 10.1016/j.ijrobp.2016.06.092  0.4
2016 Chua ML, Salcedo A, Meng A, Zhang J, Fleshner N, Fraser M, van der Kwast T, Boutros PC, Bristow RG. Genomic Architecture of Prostate Cancer at Recurrence Following Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. 96: S114. PMID 27675559 DOI: 10.1016/j.ijrobp.2016.06.280  1
2016 So J, Chua ML, Lalonde E, Pra AD, Berlin A, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, Pintilie M, ... ... Bristow RG, et al. Prognostic Significance of Tonsil Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence. International Journal of Radiation Oncology, Biology, Physics. 96: S113. PMID 27675557 DOI: 10.1016/j.ijrobp.2016.06.278  1
2016 Raziee H, Murgic J, Pintilie M, Chung P, Menard C, Bayley A, Gospodarowicz M, Warde PR, Bristow RG, Catton CN, Berlin A. Assessment of Biochemical Outcomes with Increasing Dose Escalation in Localized Prostate Cancer (PCa) Treated with Precision Image Guided Radiation Therapy (IGRT). International Journal of Radiation Oncology, Biology, Physics. 96: E228-E229. PMID 27674117 DOI: 10.1016/j.ijrobp.2016.06.1199  0.4
2016 Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, ... ... Bristow RG, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics. PMID 27526323 DOI: 10.1038/ng.3637  0.92
2016 Masella AP, Lalansingh CM, Sivasundaram P, Fraser M, Bristow RG, Boutros PC. BAMQL: a query language for extracting reads from BAM files. Bmc Bioinformatics. 17: 305. PMID 27516195 DOI: 10.1186/s12859-016-1162-y  1
2016 Castelo-Branco P, Leão R, Lipman T, Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno S, Coelho H, Gomes A, Domingos C, Apolonio JD, Schäfer G, ... Bristow RG, et al. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: A retrospective cohort study. Oncotarget. PMID 27437772 DOI: 10.18632/oncotarget.10639  0.92
2016 McPartlin AJ, Glicksman R, Pintilie M, Tsuji D, Mok G, Bayley A, Chung P, Bristow RG, Gospodarowicz MK, Catton CN, Milosevic M, Warde PR. PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer. Cancer. PMID 27219522 DOI: 10.1002/cncr.30093  0.92
2016 Jin CS, Overchuk M, Cui L, Wilson BC, Bristow RG, Chen J, Zheng G. Nanoparticle-enabled selective destruction of prostate tumor using MRI-guided focal photothermal therapy. The Prostate. PMID 27198587 DOI: 10.1002/Pros.23203  0.92
2016 Chua ML, Bristow RG. Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27166396 DOI: 10.1158/1078-0432.CCR-16-0381  0.92
2016 Her S, Cui L, Bristow RG, Allen C. Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. Radiation Research. PMID 27135970 DOI: 10.1667/Rr14315.1  0.92
2016 Wang CR, Mahmood J, Zhang QR, Vedadi A, Warrington J, Ou N, Bristow RG, Jaffray DA, Lu QB. In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer. Molecular Cancer Therapeutics. PMID 26921393 DOI: 10.1158/1535-7163.MCT-15-0862  0.92
2016 Dal Pra A, Locke JA, Borst G, Supiot S, Bristow RG. Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Frontiers in Oncology. 6: 24. PMID 26909338 DOI: 10.3389/fonc.2016.00024  0.92
2016 Boutros PC, Fraser M, van der Kwast T, Bristow RG. Clonality of localized and metastatic prostate cancer. Current Opinion in Urology. 26: 219-24. PMID 26885716 DOI: 10.1097/MOU.0000000000000279  1
2016 Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, Hermanns T, Chung P, Milosevic M, Bristow R, Warde P, Hamilton RJ, Finelli A, Jewett MAS, Zlotta AR, Sridhar SS, et al. The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis Journal of the Canadian Urological Association. 10: 25-30. DOI: 10.5489/cuaj.3315  0.92
2015 Hill RP, Bristow RG, Fyles A, Koritzinsky M, Milosevic M, Wouters BG. Hypoxia and Predicting Radiation Response. Seminars in Radiation Oncology. 25: 260-72. PMID 26384274 DOI: 10.1016/j.semradonc.2015.05.004  0.92
2015 Gani C, Coackley C, Kumareswaran R, Schütze C, Krause M, Zafarana G, Bristow RG. In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 116: 486-94. PMID 26277432 DOI: 10.1016/j.radonc.2015.08.003  0.92
2015 Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. British Journal of Cancer. 113: 425-32. PMID 26180923 DOI: 10.1038/bjc.2015.220  0.92
2015 Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Bristow RG, et al. Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 689. PMID 26018901 DOI: 10.1038/ng0615-689b  1
2015 Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, ... ... Bristow RG, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics. 47: 736-45. PMID 26005866 DOI: 10.1038/ng.3315  0.92
2015 Siadat F, Sykes J, Zlotta AR, Aldaoud N, Egawa S, Pushkar D, Kuk C, Bristow RG, Montironi R, van der Kwast T. Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. The Prostate. 75: 1277-84. PMID 25963383 DOI: 10.1002/pros.23009  0.92
2015 Berlin A, Cho E, Kong V, Howell KJ, Lao B, Craig T, Bayley A, Chung P, Gospodarowicz M, Warde P, Catton C, Bristow RG, Ménard C. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes. Practical Radiation Oncology. PMID 25899220 DOI: 10.1016/j.prro.2015.02.015  0.92
2015 Kumareswaran R, Chaudary N, Jaluba K, Meng A, Sykes J, Borhan A, Hill RP, Bristow RG. Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 25842967 DOI: 10.1016/j.radonc.2015.03.027  0.92
2015 Dodbiba L, Teichman J, Fleet A, Thai H, Starmans MH, Navab R, Chen Z, Girgis H, Eng L, Espin-Garcia O, Shen X, Bandarchi B, Schwock J, Tsao MS, El-Zimaity H, ... ... Bristow RG, et al. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. Plos One. 10: e0121872. PMID 25826681 DOI: 10.1371/journal.pone.0121872  0.92
2015 Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG. Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nature Reviews. Urology. 12: 193-204. PMID 25800395 DOI: 10.1038/nrurol.2015.50  0.92
2015 Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Bristow RG, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 367-72. PMID 25730763 DOI: 10.1038/ng.3221  1
2015 Rybak AP, Bristow RG, Kapoor A. Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget. 6: 1900-19. PMID 25595909  0.92
2015 Berlin A, Dal Pra A, Bristow RG. Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: Author reply British Journal of Radiology. 88. PMID 25363875 DOI: 10.1259/bjr.20140701  0.92
2015 Ménard C, Iupati D, Publicover J, Lee J, Abed J, O'Leary G, Simeonov A, Foltz WD, Milosevic M, Catton C, Morton G, Bristow R, Bayley A, Atenafu EG, Evans AJ, et al. MR-guided prostate biopsy for planning of focal salvage after radiation therapy. Radiology. 274: 181-91. PMID 25203127 DOI: 10.1148/radiol.14122681  0.92
2015 Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urologic Oncology. 33: 85-94. PMID 24768356 DOI: 10.1016/j.urolonc.2013.10.020  0.92
2014 Zhukova N, Ramaswamy V, Remke M, Martin DC, Castelo-Branco P, Zhang CH, Fraser M, Tse K, Poon R, Shih DJ, Baskin B, Ray PN, Bouffet E, Dirks P, von Bueren AO, ... ... Bristow RG, et al. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications. 2: 174. PMID 25539912 DOI: 10.1186/S40478-014-0174-Y  1
2014 Walker R, Louis A, Berlin A, Horsburgh S, Bristow RG, Trachtenberg J. Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 8: E783-8. PMID 25485004 DOI: 10.5489/cuaj.1970  0.92
2014 Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, ... ... Bristow RG, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet. Oncology. 15: 1521-32. PMID 25456371 DOI: 10.1016/S1470-2045(14)71021-6  0.92
2014 Berlin A, Lalonde E, Sykes J, Zafarana G, Chu KC, Ramnarine VR, Ishkanian A, Sendorek DH, Pasic I, Lam WL, Jurisica I, van der Kwast T, Milosevic M, Boutros PC, Bristow RG. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. Oncotarget. 5: 11081-90. PMID 25415046  0.92
2014 Cui L, Tse K, Zahedi P, Harding SM, Zafarana G, Jaffray DA, Bristow RG, Allen C. Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells. Radiation Research. 182: 475-88. PMID 25361396 DOI: 10.1667/Rr13642.1  0.92
2014 Kong V, Rosewall T, Chen S, Craig T, Bristow R, Milosevic M, Kwan M, Chung P. Deriving patient-specific planning target volume for partial bladder image guided radiation therapy. Practical Radiation Oncology. 4: 323-9. PMID 25194101 DOI: 10.1016/j.prro.2013.10.005  0.92
2014 Chong LC, Albuquerque MA, Harding NJ, Caloian C, Chan-Seng-Yue M, de Borja R, Fraser M, Denroche RE, Beck TA, van der Kwast T, Bristow RG, McPherson JD, Boutros PC. SeqControl: process control for DNA sequencing. Nature Methods. 11: 1071-5. PMID 25173705 DOI: 10.1038/nmeth.3094  0.92
2014 Dal Pra A, Berlin A, Kumareswaran R, Schattner AJ, Craig T, Wong D, Hodgson D, Fischer SE, Bristow RG, Dawson LA. Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 25071139 DOI: 10.1200/JCO.2013.50.9547  0.92
2014 Chan N, Ali M, McCallum GP, Kumareswaran R, Koritzinsky M, Wouters BG, Wells PG, Gallinger S, Bristow RG. Hypoxia provokes base excision repair changes and a repair-deficient, mutator phenotype in colorectal cancer cells. Molecular Cancer Research : McR. 12: 1407-15. PMID 25030372 DOI: 10.1158/1541-7786.MCR-14-0246  0.92
2014 Shuhendler AJ, Prasad P, Zhang RX, Amini MA, Sun M, Liu PP, Bristow RG, Rauth AM, Wu XY. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Molecular Pharmaceutics. 11: 2659-74. PMID 24830351 DOI: 10.1021/mp500093c  0.92
2014 Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, Wyatt AW, van der Kwast T, Collins CC, McPherson JD, Bristow RG, Boutros PC. ShatterProof: operational detection and quantification of chromothripsis. Bmc Bioinformatics. 15: 78. PMID 24646301 DOI: 10.1186/1471-2105-15-78  0.92
2014 Bristow RG, Berlin A, Dal Pra A. An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy The British Journal of Radiology. 87: 20130753. PMID 24588670 DOI: 10.1259/bjr.20130753  0.92
2014 Ramaekers CH, van den Beucken T, Bristow RG, Chiu RK, Durocher D, Wouters BG. RNF8-independent Lys63 poly-ubiquitylation prevents genomic instability in response to replication-associated DNA damage. Plos One. 9: e89997. PMID 24587176 DOI: 10.1371/journal.pone.0089997  0.92
2014 Miller JK, Buchner N, Timms L, Tam S, Luo X, Brown AM, Pasternack D, Bristow RG, Fraser M, Boutros PC, McPherson JD. Use of Sequenom sample ID Plus® SNP genotyping in identification of FFPE tumor samples. Plos One. 9: e88163. PMID 24551080 DOI: 10.1371/journal.pone.0088163  0.92
2014 Berlin A, Sykes J, Dal Pra A, Catton C, Van der Kwast T, Bristow RG. Prognostic utility of cell cycle progession score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. International Journal of Radiation Oncology, Biology, Physics. 88: 237-40. PMID 24331671 DOI: 10.1016/j.ijrobp.2013.10.009  0.92
2014 Shibata A, Moiani D, Arvai AS, Perry J, Harding SM, Genois MM, Maity R, van Rossum-Fikkert S, Kertokalio A, Romoli F, Ismail A, Ismalaj E, Petricci E, Neale MJ, Bristow RG, et al. DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Molecular Cell. 53: 7-18. PMID 24316220 DOI: 10.1016/J.Molcel.2013.11.003  0.92
2014 Taiakina D, Dal Pra A, Bristow RG. Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. Advances in Experimental Medicine and Biology. 772: 189-204. PMID 24272360 DOI: 10.1007/978-1-4614-5915-6_9  0.92
2014 Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, et al. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. International Journal of Radiation Oncology, Biology, Physics. 88: 11-7. PMID 24246724 DOI: 10.1016/J.Ijrobp.2013.09.040  0.92
2014 Milosevic MF, Pintilie M, Hedley DW, Bristow RG, Wouters BG, Oza AM, Laframboise S, Hill RP, Fyles AW. High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. International Journal of Cancer. Journal International Du Cancer. 135: 1692-9. PMID 23904154 DOI: 10.1002/ijc.28403  0.92
2013 Wang Q, Cui K, Espin-Garcia O, Cheng D, Qiu X, Chen Z, Moore M, Bristow RG, Xu W, Der S, Liu G. Resistance to bleomycin in cancer cell lines is characterized by prolonged doubling time, reduced DNA damage and evasion of G2/M arrest and apoptosis. Plos One. 8: e82363. PMID 24349265 DOI: 10.1371/journal.pone.0082363  0.92
2013 Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones GD, Meuth M, Bristow RG, Maitland NJ. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. British Journal of Cancer. 109: 3023-33. PMID 24220693 DOI: 10.1038/bjc.2013.691  0.92
2013 Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integrity. 4: 5. PMID 24152759 DOI: 10.1186/2041-9414-4-5  0.92
2013 Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, Bristow RG, Liu FF, Liu SK. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Research. 73: 6972-86. PMID 24145350 DOI: 10.1158/0008-5472.CAN-13-1657  0.92
2013 Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P, Milosevic M, Wouters BG, Bristow RG, Koritzinsky M. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6741-50. PMID 24141625 DOI: 10.1158/1078-0432.CCR-13-1787  0.92
2013 Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, ... ... Bristow RG, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5202-9. PMID 23918607 DOI: 10.1158/1078-0432.Ccr-13-1049  0.92
2013 Segatto I, Berton S, Sonego M, Massarut S, D'Andrea S, Perin T, Fabris L, Armenia J, Rampioni G, Lovisa S, Schiappacassi M, Colombatti A, Bristow RG, Vecchione A, Baldassarre G, et al. Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. Journal of Molecular Cell Biology. 5: 428-31. PMID 23899505 DOI: 10.1093/jmcb/mjt027  0.92
2013 Sridharan S, Dal Pra A, Catton C, Bristow RG, Warde P. Locally advanced prostate cancer: Current controversies and optimisation opportunities Clinical Oncology. 25: 499-505. PMID 23680106 DOI: 10.1016/j.clon.2013.04.004  0.92
2013 Trudel D, Zafarana G, Sykes J, Have CL, Bristow RG, van der Kwast T. 4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 61: 500-9. PMID 23640976 DOI: 10.1369/0022155413490946  0.92
2013 Liu TW, Macdonald TD, Jin CS, Gold JM, Bristow RG, Wilson BC, Zheng G. Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. Acs Nano. 7: 4221-32. PMID 23544841 DOI: 10.1021/Nn400669R  0.92
2013 Jelveh S, Kaspler P, Bhogal N, Mahmood J, Lindsay PE, Okunieff P, Doctrow SR, Bristow RG, Hill RP. Investigations of antioxidant-mediated protection and mitigation of radiation-induced DNA damage and lipid peroxidation in murine skin. International Journal of Radiation Biology. 89: 618-27. PMID 23484491 DOI: 10.3109/09553002.2013.782450  0.92
2013 Dodbiba L, Teichman J, Fleet A, Thai H, Sun B, Panchal D, Patel D, Tse A, Chen Z, Faluyi OO, Renouf DJ, Girgis H, Bandarchi B, Schwock J, Xu W, ... Bristow RG, et al. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Laboratory Investigation; a Journal of Technical Methods and Pathology. 93: 397-407. PMID 23399854 DOI: 10.1038/labinvest.2013.8  0.92
2013 Bristow RG, Catton C, Vesprini D. In reply to Nieder. International Journal of Radiation Oncology, Biology, Physics. 85: 581. PMID 23374994 DOI: 10.1016/j.ijrobp.2012.08.012  0.92
2013 Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE. Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Research. 73: 1611-20. PMID 23302228 DOI: 10.1158/0008-5472.CAN-12-1170  0.92
2013 Foltz WD, Wu A, Chung P, Catton C, Bayley A, Milosevic M, Bristow R, Warde P, Simeonov A, Jaffray DA, Haider MA, Ménard C. Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. Journal of Magnetic Resonance Imaging : Jmri. 37: 909-16. PMID 23097411 DOI: 10.1002/jmri.23885  0.92
2013 Fraser M, Berlin A, Ouellet V, Saad F, Bristow RG. Prostate Cancer Genomics as a Driver of Personalized Medicine Cancer Genomics: From Bench to Personalized Medicine. 233-245. DOI: 10.1016/B978-0-12-396967-5.00014-1  0.92
2012 Dal Pra A, Warde F, Ishkanian AS, Meng A, Malloff C, Lam W, Sykes J, Pintile M, Squire J, van der Kwast T, Evans A, Milosevic M, Bristow RG. TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 11. PMID 27967837 DOI: 10.1200/Jco.2012.30.5_Suppl.11  0.4
2012 McKee CM, Xu D, Cao Y, Kabraji S, Allen D, Kersemans V, Beech J, Smart S, Hamdy F, Ishkanian A, Sykes J, Pintile M, Milosevic M, van der Kwast T, Zafarana G, ... ... Bristow RG, et al. Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. The Journal of Clinical Investigation. 122: 4025-36. PMID 23041623 DOI: 10.1172/Jci59348  0.92
2012 Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. British Journal of Cancer. 107: 840-6. PMID 22871886 DOI: 10.1038/bjc.2012.345  0.92
2012 Raghavan P, Tumati V, Yu L, Chan N, Tomimatsu N, Burma S, Bristow RG, Saha D. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. International Journal of Radiation Oncology, Biology, Physics. 84: e507-14. PMID 22795803 DOI: 10.1016/j.ijrobp.2012.05.035  0.92
2012 Luo T, Yu J, Nguyen J, Wang CR, Bristow RG, Jaffray DA, Zhou XZ, Lu KP, Lu QB. Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proceedings of the National Academy of Sciences of the United States of America. 109: 10175-80. PMID 22685209 DOI: 10.1073/pnas.1203451109  0.92
2012 Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, ... ... Bristow RG, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. The Journal of Pathology. 227: 286-97. PMID 22553170 DOI: 10.1002/Path.4047  0.92
2012 Milosevic M, Warde P, Ménard C, Chung P, Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M, Catton C, Hill RP, Bristow R. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2108-14. PMID 22465832 DOI: 10.1158/1078-0432.CCR-11-2711  0.92
2012 Harding SM, Bristow RG. Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 11: 1432-44. PMID 22421153 DOI: 10.4161/cc.19824  0.92
2012 Van Der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, Bristow RG, Van Tienhoven G, Warde P, Mirimanoff RO, Bolla M. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy European Journal of Cancer. 48: 1318-1325. PMID 22405699 DOI: 10.1016/j.ejca.2012.02.003  0.92
2012 Dal Pra A, Milosevic M, Hill R, Wouters B, Warde P, Bristow RG. Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxitivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727). International Journal of Radiation Oncology, Biology, Physics. 82: 1319. PMID 22385713 DOI: 10.1016/j.ijrobp.2011.11.017  0.92
2012 Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmbhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, ... ... Bristow RG, et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. The Journal of Pathology. 227: 53-61. PMID 22294438 DOI: 10.1002/Path.3987  0.92
2012 Chopra S, Toi A, Taback N, Evans A, Haider MA, Milosevic M, Bristow RG, Chung P, Bayley A, Morton G, Vesprini D, Warde P, Catton C, Ménard C. Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 82: e441-8. PMID 22284038 DOI: 10.1016/j.ijrobp.2011.05.035  0.92
2012 Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Jurisca I, Milosevic M, ... ... Bristow RG, et al. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer. 118: 4053-62. PMID 22281794 DOI: 10.1002/Cncr.26729  0.92
2012 Kumareswaran R, Ludkovski O, Meng A, Sykes J, Pintilie M, Bristow RG. Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. Journal of Cell Science. 125: 189-99. PMID 22266907 DOI: 10.1242/jcs.092262  0.92
2012 Sanli T, Storozhuk Y, Linher-Melville K, Bristow RG, Laderout K, Viollet B, Wright J, Singh G, Tsakiridis T. Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 102: 459-65. PMID 22225791 DOI: 10.1016/j.radonc.2011.11.014  0.92
2012 Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Guns ET, van der Kwast T, Milosevic M, Bristow RG. Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. The Prostate. 72: 1295-305. PMID 22213075 DOI: 10.1002/pros.22478  0.92
2012 Ghiam AF, Cairns RA, Thoms J, Dal Pra A, Ahmed O, Meng A, Mak TW, Bristow RG. IDH mutation status in prostate cancer Oncogene. 31: 3826. PMID 22120718 DOI: 10.1038/onc.2011.546  0.92
2012 Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1015-27. PMID 22114138 DOI: 10.1158/1078-0432.CCR-11-2189  0.92
2012 Vesprini D, Catton C, Jacks L, Lockwood G, Rosewall T, Bayley A, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Nichol A, Skala M, Warde P, Bristow RG. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 83: 608-16. PMID 22099034 DOI: 10.1016/j.ijrobp.2011.07.019  0.92
2012 Locke JA, Zafarana G, Ishkanian AS, Milosevic M, Thoms J, Have CL, Malloff CA, Lam WL, Squire JA, Pintilie M, Sykes J, Ramnarine VR, Meng A, Ahmed O, Jurisica I, ... ... Bristow RG, et al. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 308-16. PMID 22048240 DOI: 10.1158/1078-0432.Ccr-11-2147  0.92
2011 Bristow RG, Ishkanian AS, Malloff C, Milosevic M, Pintilie M, van der Kwast T, Lam W. Use of genetic instability to predict biochemical recurrence in intermediate-risk prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 42. PMID 27968410 DOI: 10.1200/jco.2011.29.7_suppl.42  0.4
2011 Rashid A, Liu C, Sanli T, Tsiani E, Singh G, Bristow RG, Dayes I, Lukka H, Wright J, Tsakiridis T. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology (London, England). 6: 144. PMID 22029423 DOI: 10.1186/1748-717X-6-144  0.92
2011 Zhao H, Luoto KR, Meng AX, Bristow RG. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 101: 59-65. PMID 21903282 DOI: 10.1016/j.radonc.2011.08.013  0.92
2011 Mothersill C, Bristow RG, Harding SM, Smith RW, Mersov A, Seymour CB. A role for p53 in the response of bystander cells to receipt of medium borne signals from irradiated cells. International Journal of Radiation Biology. 87: 1120-5. PMID 21831006 DOI: 10.3109/09553002.2011.610866  0.92
2011 Kaspler P, Chen R, Hyrien O, Jelveh S, Bristow RG, Hill RP. Biodosimetry using radiation-induced micronuclei in skin fibroblasts. International Journal of Radiation Biology. 87: 824-38. PMID 21801108 DOI: 10.3109/09553002.2011.582927  0.92
2011 Ramaekers CH, van den Beucken T, Meng A, Kassam S, Thoms J, Bristow RG, Wouters BG. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 101: 190-7. PMID 21722982 DOI: 10.1016/j.radonc.2011.05.059  0.92
2011 Harding SM, Coackley C, Bristow RG. ATM-dependent phosphorylation of 53BP1 in response to genomic stress in oxic and hypoxic cells. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 99: 307-12. PMID 21680038 DOI: 10.1016/j.radonc.2011.05.039  0.92
2011 Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 10: 2218-32. PMID 21623170  0.92
2011 Dent RA, Bristow RG. In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2130-2. PMID 21519017 DOI: 10.1200/JCO.2010.34.1990  0.92
2011 Vesprini D, Narod SA, Trachtenberg J, Crook J, Jalali F, Preiner J, Sridhar S, Bristow RG. The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 5: E31-5. PMID 21470549 DOI: 10.5489/cuaj.10080  0.92
2011 Al Rashid ST, Harding SM, Law C, Coackley C, Bristow RG. Protein-protein interactions occur between p53 phosphoforms and ATM and 53BP1 at sites of exogenous DNA damage. Radiation Research. 175: 588-98. PMID 21361779 DOI: 10.1667/RR2084.1  0.92
2011 Thoms J, Goda JS, Zlotta AR, Fleshner NE, van der Kwast TH, Supiot S, Warde P, Bristow RG. Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nature Reviews. Clinical Oncology. 8: 107-13. PMID 21178999 DOI: 10.1038/nrclinonc.2010.207  0.92
2010 O'Donnell L, Panier S, Wildenhain J, Tkach JM, Al-Hakim A, Landry MC, Escribano-Diaz C, Szilard RK, Young JT, Munro M, Canny MD, Kolas NK, Zhang W, Harding SM, Ylanko J, ... ... Bristow RG, et al. The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. Molecular Cell. 40: 619-31. PMID 21055983 DOI: 10.1016/J.Molcel.2010.10.024  0.92
2010 Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, Bristow RG. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Research. 70: 8748-59. PMID 20940401 DOI: 10.1158/0008-5472.CAN-10-0944  0.92
2010 Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, Lakshman M, Gottipati P, Oliver FJ, Helleday T, Hammond EM, Bristow RG. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Research. 70: 8045-54. PMID 20924112 DOI: 10.1158/0008-5472.CAN-10-2352  0.92
2010 Choudhury A, Nelson LD, Teo MT, Chilka S, Bhattarai S, Johnston CF, Elliott F, Lowery J, Taylor CF, Churchman M, Bentley J, Knowles MA, Harnden P, Bristow RG, Bishop DT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Research. 70: 7017-26. PMID 20843819 DOI: 10.1158/0008-5472.CAN-10-1202  0.92
2010 Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology. 20: 274-81. PMID 20832020 DOI: 10.1016/j.semradonc.2010.06.001  0.92
2010 Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Seminars in Radiation Oncology. 20: 217-22. PMID 20832013 DOI: 10.1016/j.semradonc.2010.06.003  0.92
2010 Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4553-60. PMID 20823145 DOI: 10.1158/1078-0432.CCR-10-0527  0.92
2010 Zafarana G, Bristow RG. Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie! Breast Cancer Research : Bcr. 12: 111. PMID 20619004 DOI: 10.1186/bcr2597  0.92
2010 Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T. Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. International Journal of Radiation Oncology, Biology, Physics. 78: 221-9. PMID 20615625 DOI: 10.1016/j.ijrobp.2010.03.005  0.92
2010 Ishkanian AS, Zafarana G, Thoms J, Bristow RG. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncologica (Stockholm, Sweden). 49: 888-94. PMID 20590366 DOI: 10.3109/0284186X.2010.499371  0.92
2010 Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, Hill RP, Jaffray DA. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiation Research. 173: 719-28. PMID 20518651 DOI: 10.1667/Rr1984.1  0.92
2010 Tabassum A, Bristow RG, Venkateswaran V. Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: a good thing? Cancer Treatment Reviews. 36: 230-4. PMID 20079573 DOI: 10.1016/j.ctrv.2009.12.008  0.92
2010 Bhogal N, Kaspler P, Jalali F, Hyrien O, Chen R, Hill RP, Bristow RG. Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiation Research. 173: 1-9. PMID 20041754 DOI: 10.1667/RR1851.1  0.92
2009 Bristow RG. IMRT and molecular biological approaches in radiotherapy for prostate cancer. European Journal of Cancer (Oxford, England : 1990). 45: 429-30. PMID 19775659 DOI: 10.1016/S0959-8049(09)70077-2  0.92
2009 Chopra S, Foltz WD, Milosevic MF, Toi A, Bristow RG, Ménard C, Haider MA. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. International Journal of Radiation Biology. 85: 805-13. PMID 19728195 DOI: 10.1080/09553000903043059  0.92
2009 Abolmaali N, Baumann M, Bristow RG, Sibson N. Imaging radiation biology for optimised radiation therapy. International Journal of Radiation Biology. 85: 729-31. PMID 19728192 DOI: 10.1080/09553000903118653  0.92
2009 Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Ménard C, Catton CN, Diamandis EP, Bristow RG. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5576-83. PMID 19706801 DOI: 10.1158/1078-0432.CCR-09-0245  0.92
2009 Wiltshire KL, Laperriere N, Bristow RG. Prolonged survival in a patient with choroidal metastases from urothelial bladder cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: E36-E38. PMID 19672435  0.92
2009 Woodward WA, Bristow RG, Clarke MF, Coppes RP, Cristofanilli M, Duda DG, Fike JR, Hambardzumyan D, Hill RP, Jordan CT, Milas L, Pajonk F, Curran WJ, Dicker AP, Chen Y. Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. International Journal of Radiation Oncology, Biology, Physics. 74: 1580-91. PMID 19540073 DOI: 10.1016/j.ijrobp.2009.03.047  0.92
2009 Chan N, Koch CJ, Bristow RG. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Current Molecular Medicine. 9: 401-10. PMID 19519397 DOI: 10.2174/156652409788167050  0.92
2009 Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, van der Kwast T, Milosevic M, Yoshimoto M, Squire JA, Lam WL, Bristow RG. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. The Prostate. 69: 1091-100. PMID 19350549 DOI: 10.1002/pros.20959  0.92
2009 Bhogal N, Jalali F, Bristow RG. Microscopic imaging of DNA repair foci in irradiated normal tissues. International Journal of Radiation Biology. 85: 732-46. PMID 19296345 DOI: 10.1080/09553000902785791  0.92
2009 Woodward WA, Bristow RG. Radiosensitivity of Cancer-Initiating Cells and Normal Stem Cells (or what the Heisenberg Uncertainly Principle has to do with Biology) Seminars in Radiation Oncology. 19: 87-95. PMID 19249646 DOI: 10.1016/j.semradonc.2008.11.003  0.92
2009 Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, Kiltie AE, Bristow RG. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Molecular Cancer Therapeutics. 8: 203-13. PMID 19139130 DOI: 10.1158/1535-7163.MCT-08-0959  0.92
2008 Choudhury A, Elliott F, Iles MM, Churchman M, Bristow RG, Bishop DT, Kiltie AE. Analysis of variants in DNA damage signalling genes in bladder cancer. Bmc Medical Genetics. 9: 69. PMID 18638378 DOI: 10.1186/1471-2350-9-69  0.92
2008 Liu SK, Olive PL, Bristow RG. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Reviews. 27: 445-58. PMID 18516501 DOI: 10.1007/s10555-008-9137-8  0.92
2008 Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 88: 258-68. PMID 18456354 DOI: 10.1016/j.radonc.2008.04.005  0.92
2008 Bristow RG. Biomarkers of clinical trials using molecular inhibitors and radiotherapy: state-of-the-art. Preface. Cancer Metastasis Reviews. 27: 337-8. PMID 18427733 DOI: 10.1007/s10555-008-9136-9  0.92
2008 Christensen E, Evans KR, Ménard C, Pintilie M, Bristow RG. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Reviews. 27: 375-85. PMID 18427732 DOI: 10.1007/s10555-008-9139-6  0.92
2008 Supiot S, Shubbar S, Fleshner N, Warde P, Hersey K, Wallace K, Cole H, Sweet J, Tsihlias J, Jewett MA, Klotz L, Bristow RG. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 88: 53-60. PMID 18423916 DOI: 10.1016/j.radonc.2008.03.019  0.92
2008 Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Molecular Cancer Therapeutics. 7: 993-9. PMID 18413812 DOI: 10.1158/1535-7163.MCT-07-0442  0.92
2008 Cuddihy AR, Jalali F, Coackley C, Bristow RG. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Molecular Cancer Therapeutics. 7: 980-92. PMID 18413811 DOI: 10.1158/1535-7163.MCT-07-0471  0.92
2008 Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Reviews. Cancer. 8: 180-92. PMID 18273037 DOI: 10.1038/nrc2344  0.92
2008 Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 86: 407-11. PMID 18237796 DOI: 10.1016/j.radonc.2008.01.001  0.92
2008 Sarkaria JN, Bristow RG. Overview of cancer molecular radiobiology. Cancer Treatment and Research. 139: 117-33. PMID 18236714  0.92
2008 Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, Belmaaza A, Wouters B, Bristow RG. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Research. 68: 605-14. PMID 18199558 DOI: 10.1158/0008-5472.CAN-07-5472  0.92
2007 Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urologic Oncology. 25: 303-9. PMID 17628296 DOI: 10.1016/j.urolonc.2006.09.015  0.92
2007 Chan N, Milosevic M, Bristow RG. Tumor hypoxia, DNA repair and prostate cancer regression: New targets and new therapies Future Oncology. 3: 329-341. PMID 17547528 DOI: 10.2217/14796694.3.3.329  0.92
2007 Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 83: 220-30. PMID 17531338 DOI: 10.1016/J.Radonc.2007.04.016  0.92
2007 Sekhar KR, Sonar VN, Muthusamy V, Sasi S, Laszlo A, Sawani J, Horikoshi N, Higashikubo R, Bristow RG, Borrelli MJ, Crooks PA, Lepock JR, Roti Roti JL, Freeman ML. Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. Cancer Research. 67: 695-701. PMID 17234780 DOI: 10.1158/0008-5472.CAN-06-3212  0.92
2006 Dellaire G, Ching RW, Ahmed K, Jalali F, Tse KC, Bristow RG, Bazett-Jones DP. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. The Journal of Cell Biology. 175: 55-66. PMID 17030982 DOI: 10.1083/jcb.200604009  0.92
2006 Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: Targeting ATM-ATR checkpoints, DNA repair, and the proteasome Seminars in Radiation Oncology. 16: 51-58. PMID 16378907 DOI: 10.1016/j.semradonc.2005.08.007  0.92
2006 Jones K, Evans AW, Bristow RG, Levin W. Treatment of radiation proctitis with hyperbaric oxygen Radiotherapy and Oncology. 78: 91-94. PMID 16337705 DOI: 10.1016/j.radonc.2005.11.004  0.92
2005 Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Annals of the New York Academy of Sciences. 1059: 184-95. PMID 16382054 DOI: 10.1196/annals.1339.049  0.92
2005 Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Research. 65: 11597-604. PMID 16357170 DOI: 10.1158/0008-5472.CAN-05-2119  0.92
2005 Al Rashid ST, Dellaire G, Cuddihy A, Jalali F, Vaid M, Coackley C, Folkard M, Xu Y, Chen BP, Chen DJ, Lilge L, Prise KM, Bazett Jones DP, Bristow RG. Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Research. 65: 10810-21. PMID 16322227 DOI: 10.1158/0008-5472.CAN-05-0729  0.92
2005 West CM, McKay MJ, Hölscher T, Baumann M, Stratford IJ, Bristow RG, Iwakawa M, Imai T, Zingde SM, Anscher MS, Bourhis J, Begg AC, Haustermans K, Bentzen SM, Hendry JH. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. International Journal of Radiation Oncology, Biology, Physics. 62: 1264-73. PMID 16029781 DOI: 10.1016/j.ijrobp.2005.05.001  0.92
2005 Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, Bristow RG. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 76: 168-76. PMID 16026872 DOI: 10.1016/j.radonc.2005.06.025  0.92
2005 Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: Clinical and translational issues Cancer. 104: 891-905. PMID 16007687 DOI: 10.1002/cncr.21257  0.92
2005 Kumaravel TS, Bristow RG. Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Comet-FISH Breast Cancer Research and Treatment. 91: 89-93. PMID 15868435 DOI: 10.1007/s10549-004-5780-0  0.92
2005 Finlay M, Laperriere N, Bristow RG. Radiotherapy and Marfan syndrome: A report of two cases Clinical Oncology. 17: 54-56. PMID 15714930 DOI: 10.1016/j.clon.2004.06.028  0.92
2005 Faulhaber O, Bristow RG. Basis of cell kill following clinical radiotherapy Application of Apoptosis to Cancer Treatment. 293-320. DOI: 10.1007/1-4020-3302-8_13  0.92
2004 Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: Implications for genetic instability and prostate cancer progression Cancer Research. 64: 8526-8533. PMID 15574758 DOI: 10.1158/0008-5472.Can-04-1601  0.92
2004 Wiltshire K, Bristow RG, Warde P, Gospodarowicz M, Vikram B. Re: Vikram, B., The PSA conundrum [Radiother Oncol, 2004; 71(1): 1-2] [2] (multiple letters) Radiotherapy and Oncology. 73: 252-255. PMID 15542174 DOI: 10.1016/j.radonc.2004.09.006  0.92
2004 Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Molecular and Cellular Biology. 24: 8504-18. PMID 15367671 DOI: 10.1128/MCB.24.19.8504-8518.2004  0.92
2004 Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: Yes or no? Cancer and Metastasis Reviews. 23: 237-257. PMID 15197326 DOI: 10.1023/B:CANC.0000031764.81141.e4  0.92
2004 Bristow RG. Recommendations for the future of translational radiobiology research: A Canadian perspective Radiotherapy and Oncology. 70: 159-164. PMID 15028402 DOI: 10.1016/j.radonc.2004.02.002  0.92
2003 Coleman CN, Stone HB, Alexander GA, Barcellos-Hoff MH, Bedford JS, Bristow RG, Dynlacht JR, Fuks Z, Gorelic LS, Hill RP, Joiner MC, Liu FF, McBride WH, McKenna WG, Powell SN, et al. Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. Radiation Research. 160: 729-37. PMID 14640790 DOI: 10.1667/RR3096  0.92
2003 Ma BBY, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents Journal of Clinical Oncology. 21: 2760-2776. PMID 12860956 DOI: 10.1200/JCO.2003.10.044  0.92
2003 Bristow RG, Peacock J, Jang A, Kim J, Hill RP, Benchimol S. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53. Oncogene. 22: 2960-6. PMID 12771947 DOI: 10.1038/sj.onc.1206405  0.92
2003 Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: Role of apoptotic and clonogenic cell kill Prostate Cancer and Prostatic Diseases. 6: 73-85. PMID 12664070 DOI: 10.1038/sj.pcan.4500628  0.92
2002 Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, De Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Molecular and Cellular Biology. 22: 6521-32. PMID 12192050 DOI: 10.1128/Mcb.22.18.6521-6532.2002  0.92
2002 Gangopadhyay S, Jalali F, Reda D, Peacock J, Bristow RG, Benchimol S. Expression of different mutant p53 transgenes in neuroblastoma cells leads to different cellular responses to genotoxic agents. Experimental Cell Research. 275: 122-31. PMID 11925110 DOI: 10.1006/excr.2002.5493  0.92
1998 Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control International Journal of Radiation Oncology Biology Physics. 41: 347-353. PMID 9607350 DOI: 10.1016/S0360-3016(98)00062-5  0.92
1998 Bristow RG, Hu Q, Jang A, Chung S, Peacock J, Benchimol S, Hill R. Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation Oncogene. 16: 1789-1802. PMID 9583677  0.92
1997 Reitmair AH, Risley R, Bristow RG, Wilson T, Ganesh A, Jang A, Peacock J, Benchimol S, Hill RP, Mak TW, Fishel R, Meuth M. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts Cancer Research. 57: 3765-3771. PMID 9288785  0.92
1997 Bristow RG, Laperriere NJ, Tator C, Milosevic M, Wong CS. Post-operative radiotherapy for recurrent dermoid cysts of the spine: A report of 3 cases Journal of Neuro-Oncology. 33: 251-256. PMID 9195496 DOI: 10.1023/A:1005739606895  0.92
1996 Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy Radiotherapy and Oncology. 40: 197-223. PMID 8940748 DOI: 10.1016/0167-8140(96)01806-3  0.92
1996 Bristow RG, Benchimol S, Hill R. p53 protein expression or protein function? Re: AWWAD et al. IJROBP 34(2):323-332; 1996 [1] International Journal of Radiation Oncology Biology Physics. 35: 1123-1124. PMID 8751424 DOI: 10.1016/0360-3016(96)85887-1  0.92
1996 Bristow RG, Brail L, Jang A, Peacock J, Chung S, Benchimol S, Hill RP. P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection International Journal of Radiation Oncology Biology Physics. 34: 341-355. PMID 8567335 DOI: 10.1016/0360-3016(95)02023-3  0.92
1995 Peacock JW, Chung S, Bristow RG, Hill RP, Benchimol S. The p53-mediated G1 checkpoint is retained in tumorigenic rat embryo fibroblast clones transformed by the human papillomavirus type 16 E7 gene and EJ-ras Molecular and Cellular Biology. 15: 1446-1454. PMID 7862138  0.92
1994 Bristow RG, Jang A, Peacock J, Chung S, Benchimol S, Hill RP. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras Oncogene. 9: 1527-1536. PMID 8183546  0.92
1991 Pardo FS, Bristow RG, Taghian A, Ong A, Borek C. Role of transfection and clonal selection in mediating radioresistance. Proceedings of the National Academy of Sciences of the United States of America. 88: 10652-6. PMID 1961732  0.92
1990 Bristow RG, Hill RP. Comparison between in vitro radiosensitivity and in vivo radioresponse in murine tumor cell lines II: in vivo radioresponse following fractionated treatment and in vitro/in vivo correlations International Journal of Radiation Oncology, Biology, Physics. 18: 331-345. PMID 2303364 DOI: 10.1016/0360-3016(90)90098-5  0.92
1990 Bristow RG, Hardy PA, Hill RP. Comparison between in vitro radiosensitivity and in vivo radioresponse of murine tumor cell lines I: parameters of in vitro radiosensitivity and endogenous cellular glutathione levels International Journal of Radiation Oncology, Biology, Physics. 18: 133-145. PMID 2298617 DOI: 10.1016/0360-3016(90)90277-Q  0.92
1989 Bristow RG, Wood RE, Clark GM. Thyroid dose distribution in dental radiography Oral Surgery, Oral Medicine, Oral Pathology. 68: 482-487. PMID 2797745 DOI: 10.1016/0030-4220(89)90150-3  0.92
1989 Wood RE, Bristow RG, Clark GM, Nussbaum C, Taylor KW. Technique-dependent decrease in thyroid absorbed dose for dental radiography. Health Physics. 56: 893-901. PMID 2722512  0.92
Show low-probability matches.